InMotion Orthopaedic Research Center, Memphis, Tennessee, USA.
J Cell Biochem. 2010 Feb 1;109(2):302-11. doi: 10.1002/jcb.22418.
Fracture repair is a complex process involving timed cellular recruitment, gene expression, and synthesis of compounds that regenerate native tissue to restore the mechanical integrity, and thus function of injured bone. While the majority of fractures heal without complication, this takes time and a subset of patients ( approximately 10%) experience healing delays, extending their morbidity and treatment costs. Consequently, there is a need for efficacious therapeutics for the intervention of fracture healing. Recent studies into the molecular control of fracture repair and advances in the understanding of the skeleton as a whole have resulted in the identification of numerous novel targets and compounds for such intervention. These include traditional agents such bone morphogenetic proteins and other growth factors, but also relatively newer compounds such as parathyroid hormone and modulators of the Wnt signaling pathway. These agents, along with others, are discussed in the current article in terms of their investigative status and potential for clinical implementation. Hopefully, these agents, as well as others yet to be discovered, will demonstrate sufficient clinical utility for successful intervention of fracture healing. This may have significant implications for the duration of morbidity and costs associated with traumatic bone fractures.
骨折修复是一个复杂的过程,涉及到细胞的定时募集、基因表达以及合成化合物,这些化合物可以再生原生组织,恢复受伤骨骼的机械完整性和功能。虽然大多数骨折能够在没有并发症的情况下愈合,但这需要时间,一部分患者(约 10%)会出现愈合延迟,从而延长了他们的发病和治疗成本。因此,需要有效的治疗方法来干预骨折愈合。最近对骨折修复的分子控制以及对整个骨骼的理解的研究,已经确定了许多用于这种干预的新靶点和化合物。这些靶点和化合物包括传统的骨形态发生蛋白和其他生长因子等药物,但也包括相对较新的甲状旁腺激素和 Wnt 信号通路调节剂等药物。本文将讨论这些药物以及其他药物的研究现状及其在临床应用中的潜力。希望这些药物以及尚未发现的其他药物能够在骨折愈合的干预方面显示出足够的临床应用价值。这可能对与创伤性骨折相关的发病和治疗成本的持续时间产生重大影响。